3 Healthcare Stock Stories Prescribed For Investors

Humana (NYSE:HUM): Current price $78.67

Humana announced it intends to add around 500 Telesales Specialists and leadership jobs in four states to its full-time Direct Marketing Services Telesales workforce. These new jobs will back Humana’s DMS retail sales and enrollment operations, and will be located at Humana call centers around the country, including 2 in Florida, one each in Wisconsin, Arizona, and Texas. The telesales and client services positions will supply national retail phone sales and enrollment support for Humana’s Medicare benefit plans and senior products, along with individual health and specialty products.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HUM

POZEN (NASDAQ:POZN): Closing price $4.68

The firm has announced the submission of a New Drug Application to the FDA for the marketing approval of PA32540/PA8140. Both products are coordinated-delivery tablets combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core. Until regulatory approval, an indication is sought for the use of PA tablets for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

POZN

Teva Pharmaceutical Industries (NYSE: TEVA) Closing price $38.43

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries, and Alexza Pharmaceuticals (NASDAQ:ALXA) announced Wednesday that they have entered into an exclusive United States license and supply agreement for Adasuve (loxapine) inhalation powder 10 mg for the acute treatment of agitation connected with with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all domestic commercial and clinical activities for the drug, including domestic post-approval clinical evaluations, and has gained the rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TEVA

Don’t Miss: Is Molycorp Showing Signs of Life?

More Articles About:    

More from The Cheat Sheet